Latest Breaking News On - Lisenior director - Page 1 : comparemela.com

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomLina liseniorCorporate communicationsIntellia therapeutics incIntellia therapeuticsIan karpsenior vice presidentInvestor relationsLisenior director

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomLina liseniorJohn leonardExchange commissionEuropean academy of allergyEuropean commissionRegulatory agencyEuropean medicines agencyClinical immunology hybrid congressDrug administrationIntellia therapeutics incCorporate communicationsIntellia therapeuticsintellia therapeutics incNew england journalIntellia presidentChief executive officer

Intellia Therapeutics (NTLA) Receives FDA Clearance of IND to Initiate a Phase 3 Trial of NTLA-2001

Intellia Therapeutics (NTLA) Receives FDA Clearance of IND to Initiate a Phase 3 Trial of NTLA-2001
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJohn leonardLina liseniorIntellia therapeutics incExchange commissionCorporate communicationsDrug administrationIntellia therapeuticsInvestigational new drugIntellia presidentChief executive officer john leonardNobel prize winningAmyloidosis transthyretinIntellia therapeuticsintellia therapeuticsLooking statementsthisPrivate securities litigation reform act

Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesUnited kingdomJohn leonardBill chaseLina liseniorVivo program updatesDrug administrationCompany at the marketExchange commissionCorporate communicationsRegeneron pharmaceuticals incEuropean academy of allergyIntellia therapeutics incClinical trial applicationIntellia president

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomLina liseniorJohn leonardKallikrein reductionasTimothyj craigEuropean academy of allergyBiomedical sciences at penn state universityIntellia therapeutics incExchange commissionCorporate communicationsExtended phaseEuropean academyClinical immunologyHybrid congressIntellia presidentChief executive officer